Drug
Bortezomib (B)
Bortezomib (B) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_1
1
25%
Ph phase_2
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Not yet recruiting2
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
recruiting125%
completed125%
not_yet_recruiting250%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_3
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287
not_yet_recruitingphase_3
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
NCT07624513
recruitingphase_1
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647
completedphase_2
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
NCT00114738
Clinical Trials (4)
Showing 4 of 4 trials
NCT07671287Phase 3
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07624513Phase 3
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
NCT06900647Phase 1
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT00114738Phase 2
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4